Subacute cutaneous lupus erythematosus
SCLE; subacute cutaneous LE; anti-Ro-positive lupus skin disease
Subacute cutaneous lupus erythematosus (SCLE) is a photodistributed inflammatory dermatosis defined by annular polycyclic or papulosquamous (psoriasiform) plaques on sun-exposed sites. SCLE is strongly associated with anti-Ro/SSA (and to a lesser extent anti-La/SSB) antibodies, present in > 80% of patients. Drug-induced SCLE accounts for ~ 20% of cases β most commonly from thiazide diuretics, calcium-channel blockers, terbinafine, proton-pump inhibitors and TNF-Ξ± inhibitors. Paraneoplastic SCLE is rare but real, particularly with breast, lung and gastric cancers. SCLE typically does not scar (unlike DLE) but post-inflammatory dyspigmentation is common. Approximately 10β15% of patients have or develop SLE.
Clinical features
- Two principal morphological patterns:
- Annular polycyclic β ring-like erythematous plaques with central clearing.
- Papulosquamous (psoriasiform) β scaly erythematous plaques resembling psoriasis.
- Photodistributed β V of the neck, upper chest, shoulders, upper back, dorsal forearms; face often relatively spared.
- Usually non-scarring but post-inflammatory dyspigmentation is common.
- Female predominance (~ 4:1); peak age 40β50.
- Photosensitivity is prominent; many patients note seasonal worsening.
Serology
- Anti-Ro / SSA β present in > 80% of SCLE patients; sensitive but not specific.
- Anti-La / SSB β frequently coexists.
- ANA β positive in ~ 60%.
- Anti-Ro/SSA crosses the placenta β risk of neonatal lupus (most commonly cutaneous); congenital complete heart block occurs in only ~1β2% of anti-Ro-positive pregnancies. Conversely, anti-Ro/La antibodies are present in > 85% of mothers of infants with isolated congenital heart block.
- Mild lymphopenia, thrombocytopenia common.
- Anti-dsDNA, anti-Sm β generally negative; positivity suggests SLE.
Drug-induced SCLE
- ~ 20% of SCLE cases are drug-induced.
- Common culprits:
- Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide).
- Calcium-channel blockers (nifedipine, diltiazem, verapamil).
- ACE inhibitors.
- Terbinafine.
- Proton-pump inhibitors (omeprazole, lansoprazole).
- TNF-Ξ± inhibitors (infliximab, etanercept, adalimumab).
- Chemotherapy (taxanes, gemcitabine).
- Statins, NSAIDs, beta-blockers.
- Resolution typically within 6β8 weeks of drug withdrawal.
- Always take a detailed drug history at SCLE diagnosis.
Paraneoplastic SCLE
- Rare but recognised β particularly with:
- Breast adenocarcinoma.
- Lung carcinoma.
- Gastric / GI adenocarcinoma.
- Hepatocellular carcinoma.
- Haematological malignancies β lymphoma, leukaemia.
- Age > 65, treatment-refractory SCLE, atypical features or co-existing constitutional symptoms should prompt occult-malignancy workup.
- Resolution of SCLE may follow successful cancer treatment.
Management
- Strict photoprotection β SPF 50+ broad-spectrum daily, UV-protective clothing, sun avoidance.
- Identify and withdraw offending drug if suspected.
- Topical superpotent corticosteroid; topical tacrolimus / pimecrolimus.
- Hydroxychloroquine 200β400 mg daily β first-line systemic; check G6PD; ophthalmology screening.
- Methotrexate, mycophenolate, azathioprine for refractory disease.
- Anifrolumab, belimumab β emerging biologics.
- Workup for SLE β ANA, ENA, dsDNA, complement, urinalysis.
- Annual surveillance for SLE progression.
- Consider cancer screen in age > 65 or atypical / refractory cases.
References
- Sontheimer RD. Subacute cutaneous lupus erythematosus β review. J Am Acad Dermatol; 1989 (original).
- Marzano AV et al. Drug-induced subacute cutaneous lupus erythematosus β systematic review. Br J Dermatol; 2011.
- O'Kane D et al.; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. 2021;185(6):1112-1123.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.